Colorectal Neuroendocrine Tumor
Associated Genetic Biomarkers
NCI Definition: A well differentiated, low or intermediate grade tumor with neuroendocrine differentiation that arises from the colon or rectum. 
Colorectal neuroendocrine tumors most frequently harbor alterations in SF3B1, FLT4, USP9X, SETD2, and ROS1 .
SF3B1 Mutation, FLT4 Mutation, SETD2 Mutation, ROS1 Mutation, and NOTCH1 Mutation are the most common alterations in colorectal neuroendocrine tumor .
Of the biomarker-directed therapies for colorectal neuroendocrine tumor, 1 is FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting .
There are 2 clinical trials for colorectal neuroendocrine tumor, of which 2 are open and 0 are completed or closed. Of the trials that contain colorectal neuroendocrine tumor as an inclusion criterion, 2 are phase 2 (2 open).
Abemaciclib and pembrolizumab are the most common interventions in colorectal neuroendocrine tumor clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.